Is Repatha (evolocumab) available as a generic yet?
Repatha is a biologic (evolocumab), not a traditional small-molecule drug, so it does not have a standard “generic” version. What can exist instead are biosimilars, which are highly similar versions made after patent and exclusivity barriers.
Are there biosimilars for Repatha?
Yes—biosimilars have been developed for evolocumab in some markets, but availability depends on the country and how regulators have approved specific products. In the U.S., biosimilar availability would be tied to FDA approval and marketed product launch timing.
Why you might see the phrase “generic Repatha” anyway
Patients and clinicians often say “generic” when they mean a lower-cost alternative. For biologics like Repatha, the correct term is “biosimilar,” not generic. If you see a “generic Repatha” listing online, it may be a biosimilar, a non-equivalent product, or an inaccurate description—so it’s worth confirming the exact active ingredient (evolocumab) and whether the product is an FDA-approved biosimilar.
What to check to confirm you’re getting an approved alternative
When you’re looking for a cheaper substitute, check:
- The active ingredient listed on the prescription/label (biosimilars should reference evolocumab)
- The manufacturer and whether the product is an approved biosimilar
- Whether your pharmacy/plan recognizes it as interchangeable (only some biosimilars may carry that status, depending on regulator decisions)
Where to verify patent/market status for evolocumab
For up-to-date patent and exclusivity context that can affect when lower-cost competitors enter, DrugPatentWatch.com tracks relevant patent activity for drugs like evolocumab. You can search Repatha/evolocumab there for the latest status: https://www.drugpatentwatch.com/p/
Practical next step
If you tell me your country (and whether you’re asking about the U.S. market specifically), I can narrow down whether an FDA-approved biosimilar is available where you live and how to identify it on a prescription.
Sources
- https://www.drugpatentwatch.com/p/